In wake of IL-2 shutdown, Nektar lets go of 500+ staffers as it promises a turnaround
For years, NKTR-214 — also known as bempeg, short for bempegaldesleukin — was the star of the show at Nektar Therapeutics, with the promise of targeting IL-2 that no other immunotherapy developer could. The drug inspired a $3.6 billion deal with Bristol Myers Squibb and hawked the attention of analysts and investors alike.
So as Nektar Therapeutics prepares for a future without it, the changes are drastic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.